Proceedings (Baylor University. Medical Center) · 2026
Hormonal therapy and cardiovascular risk in polycystic ovary syndrome: a propensity-matched cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Varma Revati, Ilelaboye Ayodeji, Ugwuja Ferdinand, Nubla Adrian, Dispagna Marco, Chandi Paras Singh, Manjunath Keerthana, Philip Anil, Kazintet Yosef, Okorigba Efeturi, Akande Yetunde
Аннотация
BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with increased cardiovascular disease risk. Hormonal therapy is a cornerstone of PCOS management, yet its long-term cardiovascular safety remains uncertain.
METHODS: This retrospective cohort study using TriNetX included adult women with PCOS stratified by hormonal therapy initiation within 1 month of diagnosis versus never receiving therapy. One-to-one propensity score matching was performed. The primary outcome was major adverse cardiovascular events (MACE). Cox proportional hazards models estimated hazard ratios (HRs).
RESULTS: After matching, 104,849 patients were included per cohort. Over 1-year follow-up, hormonal therapy was associated with a lower risk of MACE (hazard ratio [HR] 0.72; 95% confidence interval 0.62-0.83), all-cause mortality (HR 0.68; 0.57-0.80), hospitalization (HR 0.55; 0.54-0.57), and atrial fibrillation (HR 0.76; 0.62-0.94) (all P < 0.001). Risks of myocardial infarction, stroke, heart failure, arrhythmias, and venous thromboembolism were similar between groups.
CONCLUSIONS: Hormonal therapy in PCOS was associated with reduced MACE, mortality, and hospitalization without increased thrombotic or arrhythmic risk, supporting cardiovascular safety and potential cardioprotective effects.
METHODS: This retrospective cohort study using TriNetX included adult women with PCOS stratified by hormonal therapy initiation within 1 month of diagnosis versus never receiving therapy. One-to-one propensity score matching was performed. The primary outcome was major adverse cardiovascular events (MACE). Cox proportional hazards models estimated hazard ratios (HRs).
RESULTS: After matching, 104,849 patients were included per cohort. Over 1-year follow-up, hormonal therapy was associated with a lower risk of MACE (hazard ratio [HR] 0.72; 95% confidence interval 0.62-0.83), all-cause mortality (HR 0.68; 0.57-0.80), hospitalization (HR 0.55; 0.54-0.57), and atrial fibrillation (HR 0.76; 0.62-0.94) (all P < 0.001). Risks of myocardial infarction, stroke, heart failure, arrhythmias, and venous thromboembolism were similar between groups.
CONCLUSIONS: Hormonal therapy in PCOS was associated with reduced MACE, mortality, and hospitalization without increased thrombotic or arrhythmic risk, supporting cardiovascular safety and potential cardioprotective effects.